Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer’s Dementia
Md. Sahab Uddin, M. M. Rahman, Mohammad Abu Sufian, Philippe Jeandet, Ghulam Md Ashraf, May Bin‐Jumah, Shaker A. Mousa, Mohamed M. Abdel‐Daim, Muhammad Furqan Akhtar, Ammara Saleem, Md. Shah Amran
Abstract
Alzheimer's disease (AD) is the most common form of dementia, which causes abnormalities in learning, thinking, memory, as well as behavior. Generally, symptoms of AD develop gradually and aggravate over time, and consequently severely interfere with daily activities. Furthermore, obesity is one of the common risk factors for dementia. Dysregulation of adipokine and adipocyte dysfunction are assumed to be accountable for the high risk of obesity in people that develop many related disorders such as AD. Moreover, it has been observed that the dysfunction of adipose is connected with changes in brain metabolism, brain atrophy, cognitive decline, impaired mood, neuroinflammation, impaired insulin signaling, and neuronal dysfunction in people with obesity. Conversely, the pathological mechanisms, as well as the molecular players which are involved in this association, have been unclear until now. In this article, we discuss the impact of adiponectin (AdipoQ) on obesity-related Alzheimer's dementia.